Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.20.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Schedule of changes in options outstanding

    Number
of
Options
    Weighted
Average
Exercise
Price For
Share
    Weighted
Average
Remaining
Contractual
Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding and expected to vest at December 31, 2020     3,615,602     $ 19.96       9.2     $ 74,837,043  
Granted     600,000     $ 39.24       9.96     $ -  
Exercised     (2,434 )   $ 30.00       -     $ -  
Forfeited     (215,312 )   $ 21.58       -     $ -  
Outstanding and expected to vest at March 31, 2020     3,997,856     $ 22.76       9.05     $ 60,969,194  
Options exercisable at March 31, 2020     834,719     $ 9.61       7.82     $ 21,228,752  

Schedule of changes in outstanding warrants
    Number of
Shares
    Weighted
Average
Exercise
Price Per
Share
 
Outstanding and vested at December 31,2020     3,646,872     $ 6.83  
                 
Exercised     (484,117 )     7.22  
Forfeited     (2,040 )     16.00  
Outstanding and vested at March 31, 2020     3,160,715     $ 6.79  
Schedule of stock-based compensation expense
    Three
Months
Ended
March 31,
2020
    Three
Months
Ended
March 31,
2019
 
Research and development   $ 3,293,000     $ 36,200  
General and administrative     1,746,400       358,500  
Total   $ 5,039,400     $ 394,700